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Abstract. From early description by Charcot, the classification of the Amyotrophic Lateral Sclerosis (ALS) is evolving
from a subtype of Motor Neuron (MN) Disease to be considered rather a multi-systemic, non-cell autonomous and
complex neurodegenerative disease. In the last decade, the huge amount of knowledge acquired has shed new insights on the
pathological mechanisms underlying ALS from different perspectives. However, a whole vision on the multiple dysfunctional
pathways is needed with the inclusion of information often excluded in other published revisions. We propose an integrative
view of ALS pathology, although centered on the synaptic failure as a converging and crucial player to the etiology of the
disease. Homeostasis of input and output synaptic activity of MNs has been proved to be severely and early disrupted and
to definitively contribute to microcircuitry alterations at the spinal cord. Several cells play roles in synaptic communication
across the MNs network system such as interneurons, astrocytes, microglia, Schwann and skeletal muscle cells. Microglia
are described as highly dynamic surveying cells of the nervous system but also as determinant contributors to the synaptic
plasticity linked to neuronal activity. Several signaling axis such as TNF/TNFR1 and CX3CR1/CX3CL1 that characterize
MN-microglia cross talk contribute to synaptic scaling and maintenance, have been found altered in ALS. The presence
of dystrophic and atypical microglia in late stages of ALS, with a decline in their dynamic motility and phagocytic ability,
together with less synaptic and neuronal contacts disrupts the MN-microglia dialogue, decreases homeostatic regulation of
neuronal activity, perturbs “on/off” signals and accelerates disease progression associated to impaired synaptic function and
regeneration. Other hotspot in the ALS affected network system is the unstable neuromuscular junction (NMJ) leading to
distal axonal degeneration. Reduced neuromuscular spontaneous synaptic activity in ALS mice models was also suggested
to account for the selective vulnerability of MNs and decreased regenerative capability. Synaptic destabilization may as well
derive from increased release of molecules by muscle cells (e.g. NogoA) and by terminal Schwann cells (e.g. semaphorin
3A) conceivably causing nerve terminal retraction and denervation, as well as inhibition of re-connection to muscle fibers.
Indeed, we have overviewed the alterations on the metabolic pathways and self-regenerative capacity presented in skeletal
muscle cells that contribute to muscle wasting in ALS. Finally, a detailed footpath of pathologic changes on MNs and
associated dysfunctional and synaptic alterations is provided. The oriented motivation in future ALS studies as outlined in
the present article will help in fruitful novel achievements on the mechanisms involved and in developing more target-driven
therapies that will bring new hope in halting or delaying disease progression in ALS patients.
Keywords: ALS, muscle, microglia, motor neuron, synapses, neuromuscular junction
∗Correspondence to: Caty Casas Louzao, Unitat de Fisiologia
Me`dica, Edif. M, Universitat Auto`noma de Barcelona, E-08193
Bellaterra, Barcelona, Spain. Tel.: +34 935811324; Fax: +34
935812986; E-mail: Caty.Casas@uab.cat.
1Both authors contribute equally.
ISSN 2213-6304/15/16/$35.00 © 2015/2016 – IOS Press and the authors. All rights reserved
This article is published online with Open Access and distributed under the terms of the Creative Commons Attribution Non-Commercial License.
160 C. Casas et al. / Integrating Mechanisms in ALS
HISTORY, PATHOLOGICAL FEATURES
AND ALS-ASSOCIATED GENETIC
MUTATIONS
Jean-Martin Charcot in 1869 [1] was the first physi-
cian to clearly isolate amyotrophic lateral sclerosis
(ALS) from the other sclerosis by linking symptoms
to motor neurons (MNs) that originate in the spinal
cord (SC) [2, 3]. At the moment, even if we have
no marker for diagnosis or prognosis, the disease
is recognized by the severe degeneration of lower
(spinal and bulbar) and upper (corticospinal) MNs [4]
although clinical presentations may differ. It is con-
sidered a rare disease with an incidence from 1.2 to
4 per 100,000 patients in Caucasians [5, 6]. Approxi-
mately two thirds of ALS patients have a spinal form
of the disease (limb onset) and evidence symptoms
related to focal muscle weakness and wasting which
may start either distally or proximally in the upper and
lower limbs. Gradually, spasticity may develop in the
weakened atrophic limbs, affecting manual dexter-
ity and gait. ALS patients with bulbar onset usually
complain from dysarthria and dysphagia for solids
or liquids, with limb symptoms developing either
simultaneously with bulbar symptoms or within 1–2
years. Paralysis is progressive and leads to death
due to respiratory failure within 2–3 years for bul-
bar onset cases and within 3–5 years for limb onset
[7]. Although initially characterized by this progres-
sive muscle atrophy, the term “lateral sclerosis” refers
to a distinctive anatomo-pathological trait of harden-
ing of the anterior and lateral corticospinal tracts, the
major efferent motor conduits to the spinal cord, and
alterations in the corpus callosum, [8] suggesting that
it is a complex multi-component disease.
This simple vision of considering ALS as a type
of MN disease has been challenged nowadays due
to the evidences resulting from different sources
of research. Applications of neuroimaging such us
magnetic resonance imaging (MRI), magnetic reso-
nance spectroscopy or diffusion tensor imaging have
revealed the involvement of diffuse brain presenta-
tions. At cortical level, premotor and motor regions
seem dominant although frontal and anterior tem-
poral regions, in addition to subcortical pathways,
are also key structures [9]. Because motor planning,
motor abstraction, emotional expression, and lan-
guage are all affected in ALS, some authors demand
that ALS should be considered as a result of a sys-
tem degeneration due to network failure instead of
focusing on individual neuronal populations [10].
From the systemic point of view, ALS seems to
be restricted not only to the nervous system but
also to include whole-body physiology. In particu-
lar, energy homeostasis is compromised in patients
with ALS, which has notable clinical implications
such as weight loss, hypermetabolism, and hyper-
lipidaemia. These abnormalities correlate with the
duration of survival [11]. Finally, more recently, some
authors highlight alterations in all the compounds of
the neurovascular unit [12], comprising the existence
of interactions between the vascular and neural cells
[13] in ALS patients and animal models [14–16] as
contributors to the disease pathogenesis. Despite MN
cell loss is the critical hallmark during the course
of the disease [17], other cells are considered major
determinants in the onset and ALS progression such
as astrocytes [18], microglia [19], oligodendrocytes
[20], muscle cells [21], or accepted as contributors,
such as lymphocytes [22, 23], pericytes [24] and
interneurons [25].
Besides these changes in the physiopathological
perspective of ALS, another important source of new
evidences comes from genetic research. Mutations in
the gene encoding the ubiquitously expressed Cu/Zn-
superoxide dismutase (SOD1), the first discovered
in 1993 [26], were found to cause the familial ALS
(fALS) in approximately 10 to 20% of ALS cases
[27]. Since then, 164 mutations have been found in
such gene [28]. It is at present unclear whether all
mutations are pathogenic but studies producing at
their understanding have produced a large amount
of data thanks to the generation of ALS transgenic
models carrying those mutations [29]. The transgenic
SOD1 mouse carrying the substitution of glycine
at residue 93 by alanine (tgSOD1G93A) is the most
widely studied model of ALS [30]. These mice are
normal at birth, but begin to develop MN dysfunctions
at 11 weeks of age that progress from hindlimbs to
forelimbs presenting as weakness, tremors, reduced
extension reflex, total paralysis, and, finally, death
[31, 32]. Several transgenic mouse strains expressing
the human SOD1 gene with different mutations, have
been generated to date for studying the disease patho-
genesis [33] that also present embryonic and neonatal
abnormalities in MNs and SC circuitry far earlier than
any symptomatic manifestation appear [34, 35]. Later
on, other genes were reported to be implicated as well,
which have been recently reviewed [36]. To date, 47
missense and one truncating mutations were found
in fALS and sporadic (sALS) patients [27]. Among
these genes, mutations in TAR-DNA binding protein
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(TARDBP or TDP-43) and fused in sarcoma (FUS)
[27] have revealed its importance in the degeneration
of MNs and in the so called continuum between ALS
and Fronto-Temporal Lobar Degenerationa (FTLD),
which is present in 45% of cases of ALS [37].
Recently, it was suggested that TDP-43 dysfunc-
tion is mainly localized in SC astrocytes, which
will trigger MN degeneration [38]. Indeed, astrocytes
expressing mutant SOD1 and TDP-43 were shown to
cause the death of MNs trough a common pathogenic
pathway that involves nitrosative stress [39]. Intrigu-
ingly, measurements of TDP-43 in cerebrospinal fluid
(CSF) and blood revealed its limited role as a diag-
nostic tool [40]. Finally, the most common genetic
abnormality in in families with FTLD or ALS has
recently been mapped to a non-coding repeat expan-
sion in the gene C9ORF72 at 9p21 (reviewed in [41])
Strikingly, this hexanucleotide repeat accounts for up
to 40% of fALS and 7% of sALS [5]. The contribution
of all these mutations to the pathology is mentioned
in the section below.
Thus, ALS turns out to be a multi-systemic,
non-cell autonomous and complex neurodegenera-
tive disease that requires an integrative vision. In the
last decade the huge amount of knowledge acquired
has shed insights into the pathological mechanisms
underlying ALS from different perspectives such as
genetics and proteomics, and longitudinal studies
have contributed to improve our understanding on
disease progression. However, more than ever, is time
to have a whole vision on the several determinants
implicated in ALS to better focus future research on
identifying new targets and discovering novel effica-
cious therapies that make a substantial difference for
the outcome of ALS patients. Although pretending
to draw an integrative vision to ALS pathology and
complexity we always kept in mind the synaptic fail-
ure as an important contributor to the etiology of the
disease.
ETIOPATHOGENESIS: DYING BACK,
DYING FORWARD AND SYNAPTIC
FAILURE HYPOTHESIS
Determining the nature of the etiopathogenesis
in ALS is a difficult task. This is an issue under
intense debate nowadays due to the importance of
targeting a specific tissue for therapy. The debate has
been focused in the direction of the spreading of the
disease in the central nervous system (CNS) since
both cortical and spinal regions are affected. The so
named “Dying-Back” and “Dying-Forward” hypoth-
esis co-exist to explain the pathogenic pathways for
degenerative spreading. Both are based on a net-
work perspective that explains a decline of structural
integrity with preserved functional organization of
the motor network in ALS. While “Dying-Forward”
hypothesis claim that cortical hyperexcitability in
cortical motor areas might trigger anterograde degen-
erative process towards the SC, the “Dying-Back”
theory of pathological spread in ALS suggests that
early degeneration is more likely to be captured at
the spinal anterior horn due to weakness in neuro-
muscular connectivity rather than in the brain [42].
Cortical regions mostly affected include the precen-
tral gyrus, especially in subregions with maximal
clustering of cortical MNs (Betz cells), whose degen-
eration is considered to be a pathological hallmark
of ALS [43]. Regions functionally connected with
the motor cortex are deeply affected with a reduced
microstructural organization of the efferent conduits
that form the corticospinal tracts, interconnecting
the motor network. This functional connectivity may
allow the rapid spread of the disease. Indeed, it
has been recently hypothesized that disease might
spread contiguously or non-contiguously following
a ‘domino-prion-like’ propagation between neigh-
boring neurons in a cell autonomous or non-cell
autonomous manner. This supposition is inspired in
the sticky properties of mutant SOD1, and normal
TDP43, which can undergo a seeded aggregation sim-
ilar to prions. Both native and mutant forms of SOD1
associated with each other easily form aggregates
and fibrils under denaturing conditions [44]. Impor-
tantly, removal of the misfolded seeds does not stop
aggregation of endogenous SOD1, indicating that the
newly formed aggregates can act as templates for
the subsequent misfolding of additional native SOD1
[45] (reviewed in [46]). However, Dying-Forward
hypothesis might not be easy to demonstrate in mouse
models due to significant differences in connectiv-
ity between mice and human. Betz cells in humans
connect monosynaptically to spinal MNs through
ventral corticospinal track. However, this association
is very scarce in mouse whose corticospinal track
course mainly through the dorsal funiculi and end
on interneurons at lamina V of the dorsal horn at
the SC. Only few axons run also through dorsolat-
eral and ventral funiculi which may contact directly
to some MNs [47]. Although several alterations have
early been observed in cortical MNs in parallel to
spinal MNs, it might be improbable that this will
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occur as one being the consequence of the other in
mouse models of ALS. It would be more plausible
that noxa induction, with a crucial role in apoptosis
and MN degeneration [48, 49] will occur specifically
and importantly mainly in MNs, independently of
their location. This favors the hypothesis of a com-
plex genetic-environmental interaction as the causal
factor for MN degeneration. Factors may not only
affect MNs, but also other cells in a less degree, which
together certainly account for a toxic neuronal and
system microenvironment. Among these factors, sev-
eral have been reported to be likely contributors to the
disease such as the exposure to tobacco or some pes-
ticides or the intense practice of athleticism or soccer
as determined by epidemiological analysis [5].
Synaptic terminal degeneration is a pathologi-
cal hallmark in human ALS progression. Synapse
elimination occurred even in patients who had no
MN and corticospinal tract impairment [50, 51].
The working model whereby loss of synapses at
lower MNs plays an important role in ALS patho-
genesis is commonly referred to as the ‘synaptic
stripping’ hypothesis. Direct evidence in support
of this hypothesis comes from studies showing a
decrease in the expression of synaptic vesicle pro-
teins like synaptophysin and synapsin and syntaxin
and synaptotagmin in ALS and animal models [52,
53], which were evident in remaining MNs and
suggest a loss of synapses before neuronal loss.
Nagao and colleagues showed that expression of
the synaptic marker vesicle-acetylcholine-transferase
(VAChT) was reduced in the ventral horn of an ALS
patient, reinforcing the loss of cholinergic synapses
in lower MNs as an early event in ALS [54]. In
agreement with that, it has been recently described
that there is a marked reduction in choline acetyl-
transferase (ChAT) mRNA and protein content in the
cholinergic synaptic terminals apposed onto lumbar
spinal MNs at the early asymptomatic phase in the
tgSOD1G93A ALS model [55]. Besides, this reduc-
tion was also apparent in the cholinergic synaptic
terminals of the connections from MNs onto Ren-
shaw cells. Renshaw are glycinergic and gabaergic
inhibitory cells that receive input from motor axon
collaterals and synapse in turn on the soma of MNs
in a negative-feedback fashion (homonymous recur-
rent inhibition). These inhibitory terminals in MNs
have been observed to be reduced, preferentially the
Fig. 1. Integrative view of ALS. A. ALS is a result of the degeneration of the motor functional circuitry mainly. In humans, the corticospinal
tract (CST) allows monosynaptic connection of cholinergic Betz cells in motor cortex to spinal motor neurons (MNs). At the spinal cord,
MNs forme a microcircuitry with interneurons and other MNs to accomplish the efferent motor signaling. Cholinergic interneurons at lamina
X synapse in MNs regulate motor behavior and Renshaw inhibitory interneurons receive inputs form MN axon collaterals to synapse, that
turn to MNs and conforms a negative feedback regulation. B. ALS can be considered as a multi-component disease that affects synaptic
communication. Several terminal boutons that make synapses on MNs are structural or functional affected, such as glycinergic and cholinergic
ones. The number of glycinergic synapses from inhibitory Renshaw cells is reduced and the density of these cells has been found decreased
in later stages of ALS. Choline acetyltransferase (ChAT) content is early diminished from boutons apposed on MNs and from their terminals
on Renshaw cells. Altogether these variations match with the altered recurrent inhibition found in patients and contribute to imbalance
in inhibitory/excitatory homeostasis. MNs present altered molecular environment with incapability to accomplish several neuroprotective
programs (such as autophagy, unfolded protein response (UPR), proteosomal activity) that lead to a failure in handling protein homeostasis
and aggregation, which are related to a reduced neuronal survival. There exists a persistent dysregulation in the endoplasmic reticulum
(ER)-mitochondria calcium cycle (ERMCC) that couple energy from mitochondria to protein processing in the ER and participates in AMPA-
mediated synaptic activity. This leads to excitotoxicity and abundant reactive oxygen species (ROS) and nitric oxide (NO) production. In
addition, difficulties in vesicle trafficking may occur in soma and along the axon that difficult synaptic communication with the muscle and
other cells. Thus, the machinery for local protein translation in dendrites and synapses present alterations that involves the mRNA silencing
foci at which TDP-43 and FUS/TLS participate with consequent mRNA metabolism alterations. Microglia contribute to synaptic scaling
and maintenance by cross-talk to MNs through TNF/TNFR1, CX3CL1/CX3CR1 and CD200/CD200R axis. Activation of CX3CR1 in
microglia are part of the “off” signals that switch microglia from the activated state to the resting one, which may be interrupted in ALS,
at least in some of the ALS stages. Indeed, in later stages, microglia become non-responsive and dystrophic, a phenotype that follows
the chronic activation and the release of pro-inflammatory cytokines, such as IL1-beta and TNF-alpha. Activation of TNFR1 in neurons
classically lead to apoptosis but also increases AMPA receptors at the membrane. Besides, the composition and editing of AMPA receptors
which is altered in ALS contribute to excitotoxicity due to changes in their ion permeability. C. Neuromuscular junction (NMJ) fragility is
promoted by disturbances in several cellular components and lead to impaired MN transmission and regeneration. At the axonal terminal,
the transport is altered and, in particular, there is a reduced ChAT transport which can lead to a decrease in immediately available transmitter
pool, as well as to a reduced spontaneous acetylcholine release that weakens NMJ. Synaptic withdrawn may be induced by the release of
inhibitors of regeneration like Nogo A or Semaphorin 3A from muscle or terminal Schwann cells, respectively. Myofiber atrophy is one of
the earliest events in ALS. Muscle cell metabolism and regeneration is altered. There exists mitochondria function defects promoting ATP
reduction, disturbances of calcium buffering capacity and oxidative stress exrcerbated by muscle training and muscle hypermetabolism that
leads to a rise in oxygen species, which contribute to oxidation of mRNAs and altered miRNA biogenesis. These features contribute to a
reduced capacity for muscle regeneration accompanied by an impaired proliferative potential of satellite cells that lead this capacity. Finally,
the presence of protein aggregates in the muscle may overshoot protein clearance systems, such as proteasomal system, which contribute to
muscle wasting and energy depletion. UPS, ubiquitin-proteasome system.
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glycinergic ones [56], compromising the functional-
ity of the local SC motor circuitry. Indeed, alterations
in inhibitory neurotransmission have been reported
in ALS patients as well [57, 58], which extensively
contribute to the imbalance between inhibitory and
excitatory synaptic drive to MNs. Excitatory sig-
naling gain and/or an inhibitory loss on MNs will
increase Ca2+ influx and depolarization, favoring
excitotoxicity [59, 60]. It is not only a specific char-
acteristic that happens in the SC but also in cortical
areas. Functional studies, using transcranial magnetic
stimulation of the motor cortex, showed an increase in
the excitatory postsynaptic potentials recorded from
the contralateral extensor digitorum communis mus-
cle, a feature that Authors attribute to a marked
loss of inhibition at cortical MNs in patients with
ALS [61]. PET scanner studies [62] and in situ
hybridization [63] revealed a decrease in both the
density of the GABAA receptor and the expression
of GABAA receptor subunit mRNA, respectively, in
the motor cortex of ALS patients. Thus, all these
evidences point to a loss of synaptic homeostasis
in MNs, involving both lower and upper MNs and
resulting from a decreased activity of the inhibitory
circuits controlling MN excitability. Early alteration
in cholinergic input from interneurons and output
towards the NMJ and Renshaw cells concomitant to
loss of inhibitory glycinergic synapses and Renshaw
cells itself [64] may favor excitotoxicity definitely
compromising regulatory microcircuitry function.
GLIA CONTRIBUTION TO SYNAPTIC
DYSFUNCTION IN ALS
Astrocytes and microglia accompany MNs and
react in consonance to neuronal function. The emerg-
ing concepts of the “tripartite” synapse [65], that
includes astrocytes, and even the “quadripartite”
synapse [66, 67] that add microglial cells as well,
may better describe recent evidence indicating that
there are multiple cell types working together at
remodeling synaptic plasticity. One of the major func-
tions of microglial cells in the brain is to survey
for damage and protect neural material by orches-
trating the innate immune response [68]. Microglia
present an extremely cellular plasticity switching
from a “resting” or “surveillant” cell phenotype with
several fine processes to a globular “amoeboid” acti-
vated microglia with the ability to migrate to sites of
damage and to phagocyte cellular debris [69]. Sev-
eral evidences point to ramified “resting” microglia
as highly dynamic surveyors of the healthy brain
and determinant contributors to synaptic plasticity
[70]. In particular, microglia contact with dendritic
spines occur in a transient manner and linked to neu-
ronal activity and functional experience as shown by
Tremblay & collaborators [71]. Several molecules
that mediate microglia-neuron cross-talk have been
related to these synaptic events including some
cytokines with additional functions beyond their role
in inflammation. One of these cytokines is tumor
necrosis factor- (TNF-), whose secretion has been
recently specifically assigned to microglia but not to
astrocytes [72]. Two transmembrane receptors, TNF
receptor 1 (TNFR1) and TNFR2, were discovered
25 years ago [73]. TNFR1 is expressed ubiquitously
on almost all cell types, while TNFR2 is more lim-
ited to specific cells, as those of the immune system
[74]. However, activation of both TNFR1 and TNFR2
expression in neurons, astrocytes and oligodendro-
cytes was observed after traumatic CS injury [75].
While TNFR1 is predominantly linked to apopto-
sis and neurodegeneration, TNFR2 was shown to be
involved in tissue regeneration and neuroprotection
[76, 77].
However, TNF- levels also control basal synaptic
function and synaptic scaling plasticity [78]. Synap-
tic scaling is a form of non-associative homeostatic
plasticity allowing equilibrium between excitatory
and inhibitory inputs that works to stabilize neu-
ronal firing rates by adjusting the strength of all the
synapses of a neuron to keep firing rates roughly
constant. TNF- increases expression of surface
AMPA receptors in both primary and slice cul-
tures, hence increasing synaptic strength and synaptic
scaling [79, 80]. Both mRNA of TNF- and its pro-
apoptotic receptor TNFR1 were shown to be elevated
in late presymptomatic stage and to increase pro-
gressively along disease progression in the lumbar
SC of tgSOD1G93A mice [81]. Interestingly, cir-
culating levels of TNF- and TNFR1 were found
elevated in ALS patients, although no correlation
with disease severity was not observed [82]. In ALS,
the AMPA receptors presented an altered composi-
tion in subunit stoichiometry and editing that render
them more permeable to calcium ions [83]. For this
reason it has been considered a promising target
and several drugs have been used to drive clinical
trials although without success, probably because
the excitotoxic phenomenon represents a too early
phenomenon in disease onset. Besides the role of
microglia on the plasticity of existing synapses it may
also contribute to more profound structural changes
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by phagocyting specific subsets of synapses as it
does during developmental synaptic pruning and in
injury-related synaptic stripping events [84]. More-
over, as TNF- is released by activated microglia
one can consider neuroinflammation and excitotox-
icity as mechanistic links for microglia-astrocyte
and microglia-neuron cross-talk [85]. In these pro-
cesses, other molecular axis of neuronal-microglia
dialogue may also be implicated. Neuroprotective
signaling from MN to microglia can be medi-
ated through at least two cytokines, the chemokine
ligand 1 (CX3CL1/fractalkine) and the membrane
glycoprotein CD200 that have the correspon-
dent receptors CX3CR1 and C200R, respectively,
restricted to microglia [86, 87]. Increased expression
of microglial C200R was found in the presymp-
tomatic tgSOD1G93A mice [88] while that of
CX3CR1 was observed at disease endstage [89].
CX3CL1 signaling by healthy neurons controls the
overproduction of iNOS, IL-1, TNF, and IL-
6 [90, 91]. In addition, CX3CR1 was also shown
to play a role in cognitive function and synap-
tic plasticity [92]. Indeed, the axis has shown to
have an important role in synaptic maturation and
function since mice lacking CX3CR1 had deficits
in synaptic pruning and decreased frequency of
spontaneous excitatory post-synaptic currents, sug-
gesting immature connectivity in the knockout mice
[90]. In turn, microglial cathepsin S (CatS), a lyso-
somal/endosomal cysteine protease, seems to be
responsible for the liberation of neuronal CX3CL1
[30]. Thus, CatS-mediated modification of the perisy-
naptic environment induce a downscaling of synaptic
strength [93]. Information about the relevance of
CX3CR1-CX3CL1 axis in ALS is scarce apart from
that its disruption accelerates neurodegeneration in
the double transgenic SOD1G93A/Cx3cr1–/– mice,
which showed to survive less than the single SOD1
mutant [87].
Recent findings have underlined that toll-like
receptor 2 (TLR2) and TLR4 are critical for glia
activation. In the SC of ALS patients TLR2 was
predominantly detected in microglia whereas TLR4
was strongly expressed in astrocytes [94]. Interest-
ingly, while TLR2 evidenced to mediate inhibition of
neural progenitor cell proliferation [95] and showed
to be associated with synaptic loss, TLR4 was sug-
gested to relate with synaptic stability in the SC after
peripheral nerve injury [96]. In addition, microglial
activation was also related with TDP-43 pathology
and indicated to be an important determinant of cog-
nitive impairment in ALS [97]. Finally, dystrophic
microglia may have a determinant role to accelerate
disease progression. As suggested by Graeber and
Streit, chronic activation of microglial cells could
lead to overactivation followed by microglial dys-
trophy and degeneration [98]. This is especially
relevant in the context of aging-related disorders
since microglia response to injury during early-life
could increase the susceptibility to the develop-
ment of disease in adulthood and aging [99]. Aged
microglia present a decline in their dynamic motil-
ity through neural parenchyma, less frequent and
extensive synaptic neuronal contacts, together with a
decreased homeostatic regulation of neuronal activity
and perturbations in the “on”/off signals, as well as
increased neuroinflammatory response and oxidative
stress [70]. The presence of mutant SOD1 acting on
microglia is required to cause the disease [100] and
its scission exclusively from microglia significantly
slow disease progression [101]. Indeed, when the
mutant SOD1 microglia was replaced with microglia
expressing the wild-type SOD1 a prolonged survival
of the ALS mice was observed [102]. Besides, the
presence of mutant SOD1 intra- and extracellularly
may enhance the production and release of reactive
oxygen species (ROS), increase the inflammatory
cytokine cascade [103] and accelerate the formation
of the senescent microglial phenotype. Therefore, any
neurotoxic effect that acts at a cellular level in ALS
may affect the main functions of microglia promot-
ing its early senescence and thus reducing synapse
contacts, activity and plasticity that impede the pos-
sibility to regenerate disconnected MN.
NEUROMUSCULAR COMPONENTS
CONTRIBUTING TO SYNAPSE
FAILURE IN ALS
Cholinergic transmission towards the neuromus-
cular junction (NMJ) has also shown to be altered
in ALS models. Decreased choline acetyltransferase
(ChAT) expression and resultant reduction of acetyl-
choline (ACh) release from motor nerve ends can lead
to dysfunction of motor synapses at axon terminals
[104, 105]. Impaired neuromuscular transmission
was detected in early sALS patients [106], and a
reduced supply of releasable ACh was thought to
be the primary cause for the degeneration of motor
terminals in a dog model of hereditary spinal muscu-
lar atrophy [104, 107]. Several factors can contribute
to such issue. Recently, Tateno and collaborators
reported an interesting hypothesis based on the alter-
ations in axonal transport towards the NMJ terminal,
166 C. Casas et al. / Integrating Mechanisms in ALS
in general, and to the transport of ChAT and AChE
in particular. These molecules require binding to
a motor protein to be transported along the axon,
such as the kinesin-associated protein 3 (KAP3),
which is specifically sequestered by the presence
of misfolded SOD1 species. As a consequence, the
transport of ChAT was shown to be interrupted at
the pre-onset stage in the tgSOD1G93A mice [108]
and to accumulate in the MN soma [55]. Consid-
ering that misfolded SOD1 has been also linked to
sALS, the inhibition of ChAT transport and hence
the reduction in acetylcholine (ACh) availability may
be one of the common pathways leading to MN-
specific dysfunction in ALS. ACh is necessary for the
neurotransmission but also activates endplate recep-
tors during spontaneous release. This may explain
selective vulnerability observed between fast (more
vulnerable) and slow MN types in ALS because fast
MNs are more dependent on endplate ACh recep-
tor activation during spontaneous release that acts
then as a retrograde signaling system for regulating
their electrical properties, maintaining connectivity
and promoting regeneration [109]. Accordingly, Nau-
menko and collaborators have observed a significant
decrease in the immediately available transmitter
pool in nerve endings of tgSOD1G93A mice males
[110], likely one of the reasons for the dramatic drop
in the spontaneous mediator release and enhanced
fatigability of ALS muscles at high rate firing [111].
In this regard, a decrease in spontaneous ACh release
would consistently weaken the strength of selective
NMJ and hinder regeneration, as observed in ALS
[55, 112].
Interestingly, it was recently evidenced that matrix
metalloproteinase-9 (MMP-9) is expressed only by
fast MNs and its pharmacological inhibition revealed
to significantly delay muscle denervation [113].
MMP-9 activity was previously found enhanced in
pyramidal neurons in the motor cortex and MNs in the
SC of ALS patients [114], as well in their serum [115].
Moreover, other studies revealed that MMP-9 activity
also increase in the SC and skin of the tgSOD1G93A
mouse model, mainly in the later stages of the disease
[116]. Later, it was also shown that the extracellu-
lar media of differentiating NSC-34 MN-like cells
carrying the G93A mutation in human SOD1 also
contain increased MMP-9 activation [117]. Most
important, these Authors demonstrated that MMP-
9 activation was reduced after treatment with the bile
acid glycoursodeoxycolic acid, suggesting that it may
be a promising therapeutic strategy when consider-
ing MMP-9 as a candidate target.NMJ fragility has
long been considered a hallmark in ALS. Studies in
rodents and humans have demonstrated that axonal
retraction occurs well before the loss of cell bodies
and that intrinsic axonal mechanisms actively con-
tribute to phenotype in ALS [42, 118]. Actually, in
the tgSOD1G93A mouse model it was observed that
denervation occurred as a very early phenomena, i.e.
weeks before MN lost was noticed [119]. Such studies
also demonstrated that fast-fatigable motor units pre-
sented higher susceptibility to degenerate than slow
ones as mentioned [118, 120]. Thus NMJ degener-
ation represent early pathological targets [112]. Is
important to bear in mind that at the peripheral NMJ,
three main different cell types, i.e. motor nerve ter-
minal, terminal Schwann cells (TSC) and muscle
fibers, collaborate in the assembly and maintenance
of the synaptic apparatus. Non-myelinating, terminal
Schwann cells (TSC), phenotypically different from
those that wrap the axon in the peripheral nerve, cap
the nerve terminal covering motor terminal branches
and synaptic buttons and have a main role in regen-
eration [121]. A number of TSCs was noticed to
be significantly reduced following disease progres-
sion in the tgSOD1G93A rat muscle. In addition, it
has been reported that TSCs specifically express the
chemorepellent semaphorin 3A (Sema3A) at the fast-
fatigable-type neuromuscular synapses [122]. The
authors propose that this de novo expression of
Sema3A in the ALS rat model may impede nerve ter-
minal plasticity at specific neuromuscular synapses,
thus contributing to their early and selective loss.
Besides Sema 3A, other inhibitors for axonal
regeneration such as Nogo-A have been observed
originating from skeletal muscles, particularly from
deltoid ALS patient biopsies and in tgSOD1G93A
mice. This factor was proposed as a diagnostic [123]
and prognostic [124] marker in ALS, once corre-
lated with disease severity and motor impairment.
Consistently, the double transgenic SOD1G86R and
Nogo-A knock-out mice exhibited MN maintenance,
reduced expression of denervation markers AChrna
1 alpha and Tyr kinase and prolonged lifespan [125].
However, the specificity of this factor in ALS disease
remains controversial [126–128] as no increment of
Nogo-A serum levels has been found in patients [129]
and compensatory Nogo-B increment can under-
lay therapeutic benefits of Nogo-A knocking-out
[130].
Failure or dysfunction of either the axonal
metabolism itself or that of the skeletal muscle fibers
contribute to this NMJ fragility and MN degener-
ation [131, 132]. The post-synaptic component of
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the NMJ, the muscle, plays an essential role in
ALS axonopathy since overexpression of mutated
SOD1 enzyme exclusively in skeletal muscle showed
besides motor deficits such as spasticity and hyper-
reflexia, also abnormalities in the NMJ and a distal
axonopathy [133, 134]. However, apparent controver-
sial results in the literature make difficult to achieve
definite conclusions about muscle pathology contri-
bution to ALS. In this regard, intramuscular injection
of a lentiviral vector (not retrogradely transported to
central nervous system), encoding a siRNA against
SOD1 or specific gene excision through the Cre-
Lox-P recombinase system under creatine kinase
promoter, showing a 50% mRNA and protein reduc-
tion of mutant SOD1 exclusively in skeletal muscle
provided no benefits of muscle grip strength main-
tenance and no delayed onset or progression of the
disease [135]. However, due to the fact that even
low the level of mutant SOD1 in skeletal muscle is
able to trigger the ALS phenotype [133], reminis-
cent mutant SOD1 expression could be responsible
for such observations. Several pathological events
have been linked to muscle dysfunction in ALS and
referred to influence the NMJ connection, such as
metabolism and self-regenerative capacity. Dupuis
and co-workers, described the up regulation of mito-
chondrial uncoupling protein (UCP) correlated with
ATP reduction specifically in skeletal muscle of
ALS patients and animal models [136]; they also
demonstrated that muscle mitochondrial uncoupling
driven by this protein leads to NMJ and MN disman-
tling, while exacerbating ALS phenotype [137]. In
agreement, several Authors have reported increased
lipid and carbohydrate clearance in tgSOD1G93A
and tgSOD1G86R individual muscles at asymptomatic
stages [138–140], correlating these findings with the
muscle hypermetabolism and energy deficit. Consis-
tently, high-fat diets have demonstrated to restore
body mass, ameliorate muscle denervation and motor
deficits and prolong the lifespan in animal mod-
els. Muscle mitochondrial defects have been largely
described in skeletal muscle from ALS patients [138,
141, 142]. However, mitochondria are key intracel-
lular organelles regulating not only energy but also
other essential cellular functions, such as calcium
homeostasis or apoptotic signaling. The expression
of aberrant mutated proteins such as SOD1 in skele-
tal muscle myofibers of ALS models, as previously
described in MNs, has been proposed to interfere with
the inner membrane mitochondrial potential and the
calcium buffering capacity [143] that results in the
sequestrate of the anti-apoptotic protein Bcl-2, lead-
ing to apoptosis and development of local oxidative
stress [144, 145]. Interestingly, Wei R and colleagues
did not detect the presence of mutant protein aggre-
gates in gastrocnemius muscle of tgSOD1G93A mice
from pre-symptomatic (50 days) to terminal stages
(130 days), although a 2 to 4 fold increase in 20 S
proteasomal activity was observed. These Authors
concluded that the muscle ability to maintain a high
proteasomal activity mediated the effective clearance
of the toxic protein aggregates [146] as it had been
previously suggested in C2C12 myoblasts [147]. The
ubiquitin-proteasome system (UPS) is crucial for
maintaining muscle homeostasis, as it is required to
remove sarcomeric proteins upon changes in muscle
activity [148, 149]; excessive up-regulation through
increased proteasomal activity, ubiquitin-conjugation
or over-expression of transcripts encoding ubiquitin,
ubiquitin-conjugating enzymes, ubiquitin-protein
ligases or proteasomal subunits, leads to muscle wast-
ing [150]. Importantly, myofiber atrophy is one of the
earliest events on ALS. Studies with specific modula-
tors of this pathway would be of interest to establish
the optimal UPS activity beneficial for mutant protein
clearance but not detrimental for the maintenance of
muscle mass on ALS.
Molecular signaling alterations have been also
found in RNA processing both mRNA and miRNA.
mRNA processing was found disturbed in ALS
mouse models; consistently, oxidized mRNA species
were detected in the SC of patients, as well as in
tgSOD1G93A mice at the pre-symptomatic 45 days
[151]. Tight implication of miRNA biogenesis and
performance in muscle cells is likely to operate on
ALS since miRNA 23a, 455, 29b and 206 were up-
regulated in vastus lateralis of ALS patients [152].
Both miRNA 29 and 206 are known to promote mus-
cle regeneration and recovery after cardiotoxin or
nerve crush injury [153, 154] and ALS mouse model
genetically deficient in miR-206 showed accelerated
progression of the disease [155].
In adults, satellite cell pool, largely responsible for
the regenerative capacity in this tissue, remain qui-
escent but retain the ability to activate and reenter
cell cycle in response to signals from the cellular
niche such as muscle injury or intense physical exer-
cise. A portion of these cells proliferate and fuse
with each other or with the parental myofiber to
fully regenerate the damaged tissue, whereas the
rest remain undifferentiated and exit cell cycle to
replenish the myogenic cell pool. This process is
regulated by highly coordinated transcriptional and
translational networks in which myogenic regula-
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tory factors play a central role [156–160]. However,
in aging [161, 162], Duchenne muscular dystrophy
[163, 164] or spinal muscular atrophy [165], succes-
sive rounds of regeneration or aberrant stimuli from
the cellular niche perturb self-renewal or myogenesis
leading to depletion of the satellite cell pool or loss
of myogenic potential and muscle wasting. In line
with this, it has been recently reported an abnormal
number of satellite cells in both fast and slow-
twitch myofibers of tgSOD1G93A mouse model since
the earliest pre-symptomatic stages of the disease,
accompanied by blunted protein translation of myo-
genic regulatory factors controlling the activity of
these cells and in vitro impaired proliferative potential
[166].
Despite the uncertain mechanisms of MN degener-
ation driven by the skeletal muscle, several evidences
exist based on therapeutic benefits proportion-
ated by strategies supporting muscle homeostasis,
regenerative potential and muscle mass. Controlled
exercise improved motor function and survival in
tgSOD1G93A animal models [167] and reduced spas-
ticity and motor function loss in ALS patients
[168]. Mild physical activity has neuroprotective
benefits as promotes neurogenesis [168–170] and
increases peripheral levels of neurotrophic factors
such as BDNF (brain-derived neurotrophic factor)
[171–173] and IGF-1 [174, 175]. However, muscle
training is an inductor of oxidative stress, as markedly
increases the systemic consumption and uptake of
oxygen thus enhancing ROS production, including
the generation of the superoxide radical from the
mitochondrial electron transport chain [176]. There-
fore, despite substantial effort to establish the optimal
stage, intensity and duration of the training to maxi-
mize the potential benefits, the controversy remains
[174, 177–179]. These observations, together with
the high incidence of ALS cases within profes-
sionals developing intense physical activity, such
as soccer players [180–183], encouraged clinicians
to advice against such practice to preserve muscle
mass.
Artificial delivery of neurotrophic molecules, such
as muscle-derived but no centrally derived GDNF
(glial-derived neurotrophic factor) over-expression,
was neuroprotective in the tgSOD1G93A mice [184].
Indeed, intramuscular injections of myoblasts [185]
and mesenchymal stem cells [186] carrying vectors
encoding GDNF, expanded the survival and motor
performance of tgSOD1G93A rodents and delayed
MN loss, as shown by levels of acetylcholine recep-
tor postsynaptic clusters and ChAT or agrin-positive
end plates within the lumbar SC region. Additionally,
IGF-1 restricted expression in the skeletal mus-
cle of ALS rodents counteracted the symptoms of
the disease, exacerbated myogenesis and reduced
catabolism, thus prolonging the lifespan [21, 187,
188]. These Authors concluded that skeletal mus-
cle satellite cell activity, mediated by muscle IGF-1,
contributed to the ameliorated phenotype of the
tgSOD1G93A mice.
Overall these findings provide evidence that ALS
skeletal muscle suffer from direct neurotoxic effects
of SOD1 or other molecules and definitely affect
synaptic connectivity at the NMJ, as well as its
metabolism, contributing to the multi-systemic phe-
notype of the disease.
MN PATHOLOGY AND CONTRIBUTION
TO SYNAPTIC DYSFUNCTION IN ALS
Several years ago, some Authors suggested that
synaptic dysfunction may precede synaptic loss [51,
189, 190] and, indeed, this is a rather common
feature in other neurodegenerative diseases as well
[191]. In both sALS and fALS, molecular changes
most likely precede the clinical onset. In sALS, an
acquired defect in chromatin, DNA, RNA or pro-
teins (such as epigenetic alteration, a somatic DNA
mutation, a RNA editing error, and the misfolding of
proteins possibly due to ageing effects or environ-
mental stressors) occurs randomly in each cell, and
these defects accumulate and converge to initiate the
pathogenic process. The mechanisms involved in MN
dysfunction in ALS have been accurately detailed
recently by Cozzolino and collaborators [192]. The
discovery of new genes implicated in ALS and the
existence of common mechanisms found in most
of the genes have pointed to new insights into the
pathogenic pathways. Bioinformatics’ analysis of
their annotated functions reveal an enrichment in
processes such as endocytosis and impaired vesi-
cle (Alsin, VAPB, OPTN, VCP), axonal transport
and organelle trafficking (spatacsin), compromised
autophagy (CHMP2B) and protein degradation, in the
UPR response (UBQLN2, SIGMAR1), transcription
regulation and RNA metabolism (C9orf72, TARDBP,
ANG, SETX), as well as in mitochondria-dependent
oxidative stress. Increased levels of “classical” mark-
ers of oxidative stress, including reactive oxygen
species (ROS) and products of protein and lipid
oxidation, have been repeatedly and consistently
observed in tissues from patients and in in vitro and
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in vivo mutant SOD1 models, although its origin
is still not clear [193]. Since, mitochondria are the
major sites of formation of ROS and are particularly
susceptible to oxidative stress, the vicious cycle can
pushover mitochondrial damage. Besides, connectiv-
ity among different organelles reveal some key joined
events related to pathogenesis in ALS. As mentioned
by Cozzolino and collaborators in their review [192],
the interaction between mitochondria and endoplas-
mic reticulum (ER), termed the ER-mitochondria
calcium cycle (ERMCC), couples energy metabolism
in mitochondria and protein processing in the ER to
the synaptic activity in neurons mediated by AMPA
receptor. Therefore, ERMCC seems to mediate
AMPA receptor-mediated glutamate excitotoxicity
in MNs where a toxic shift of calcium from the
ER compartment to the mitochondrial compart-
ment causes chronic calcium depletion of the ER
and chronic mitochondrial calcium overload. The
former would trigger the protective unfolded pro-
tein response (UPR), and the latter, a consecutive
release of cell death signals through the mitochon-
drial permeability transition pore. Persistent ERMCC
dysregulation is a key pathway resulting in the accu-
mulation of misfolded proteins, failing UPR and MN
death. The failure of protein homeostatic handling
in the cell have been revealed by reported defects in
UPR, in protective autophagy and in adequate pro-
tein quality control in ALS models [194, 195], as
well as in SC tissues of human sALS patients [196].
But importantly, SOD1, OPTN, FUS/TLS & TDP-
43 are prone to aggregate when mutated, but even in
sALS, SOD1 aggregation represents a common hall-
mark [197]. It has been indicated that the increased
aggregation propensity of SOD1 mutants is related
to the decrease survival in ALS patients, further sug-
gesting that aggregation could be a major contributor
to SOD1 toxicity in such patients [198]. Importantly,
several animal models with reduced motor func-
tion presented also impaired autophagy. Conceivable,
motor defects generate high amounts of stranded
cargo that may overwhelm the autophagic apparatus.
Besides, some reports implicate these proteins also
in synaptic function. TDP43 and FUS/TLS form part
of the so-called mRNA-silencing foci that are cyto-
plasmatic supramolecular aggregates of repressed
RNA and inhibitory proteins in charge of local trans-
lation induced specifically by synaptic activity in
dendrites and synapses [199], while Optineurin is
involved in vesicle trafficking needed for synapse
maintenance [200]. The assignment of apoptosis to
the ended mechanism of neuronal death in ALS has
been for a subject of extensive debate since contro-
versial evidences have been obtained when human
samples were analyzed and matched with effects
obtained in animal models [201–204]. What seems
clear, however, is that if apoptosis exists it occurs
only as a later event of a degenerating process that
follows a “Dying Back” pattern of MN dysfunction
[192].
Analysis of transcriptomic profile in neurodegen-
erative diseases has advanced considerably in the
past 5 years. Increased scientific rigor and improved
analytical tools have led to more-reproducible data.
Many platforms for transcriptome analysis assay the
expression of the entire genome, enabling that a com-
plete biological context is captured. Gene expression
profiling pointed to dysregulation of genes related to
neuroinflammation, as well as to disruption of RNA
splicing and protein turnover, and several studies in
ALS also support the cytoskeleton involvement. Cer-
tainly, results from omics experiments will contribute
to have a more integrative vision in the pathol-
ogy of MNs and in its interaction with the cellular
neighbors. Computational biology will help systems
biology analysis to definitely ascertain the optimal
combination of therapeutic agents to end up with
the neurodegenerative process. This so-called net-
work medicine [205] has been advanced fruitfully
nowadays in cancer research and is certainly the next
frontier also for complex neurodegenerative diseases
such as ALS.
CONCLUSION
Consideration of ALS as a type of MN neu-
ron disease has evolved to be considered as a
multi-systemic, non-cell autonomous and complex
neurodegenerative disease. Dying forward and dying
back hypothesis to explain the etiology of MN
degeneration are difficult to demonstrate in exper-
imental models since rodent corticospinal circuitry
differs substantially from that of humans. In that
regard, it would be more plausible that noxa
implicated in degeneration would affect specifi-
cally and importantly MNs mainly, independently
on their location, favoring the hypothesis that com-
plex genetic-environmental interaction is indeed the
causal factor for MN degeneration. Histological and
functional analysis on microcircuitry at the SC, brain
and neuromuscular levels where MNs, interneurons,
glial and muscle cells may interplay already revealed
marked synaptic alterations that may compromise tis-
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sular homeostasis and that extensively will contribute
to the imbalance between inhibitory and excita-
tory synaptic drive to MNs. Excitatory signaling
gain and/or an inhibitory loss on MNs will increase
Ca2+ influx and depolarization, favoring excitotoxi-
city largely observed in several regions of the CNS in
patients and models. Besides, particular early affec-
tation on cholinergic transmission within the CNS
and towards the NMJ might contribute to synaptic
dysfunction first, followed by later cellular dysfunc-
tion and even selective MN degeneration. Since glial
cells, particularly microglia at the CNS and terminal
Schwann cells at the NMJ, contribute to synap-
tic remodeling and maintenance, it will be worth
focus the attention on molecules involved in cross-
talking with neurons and axons, as well as in aspects
regarding the effects of glial senescence in disease
environment and its repercussions on neuronal func-
tion failure. Finally, special emphasis on metabolism
pitfalls present in ALS patients shifted the attention
to muscle regenerative capabilities in patients and
models, which have been observed as being severely
affected. ALS skeletal muscle suffers from direct neu-
rotoxic effects of SOD1, or other molecules, which
definitely affect synaptic connectivity at the NMJ,
as well as its metabolism, contributing to the multi-
systemic phenotype of the disease. With all these
landscape together with intrinsic abnormalities, MN
function evolve towards dysfunction of its main cel-
lular processes related to transcription, translation
and vesicle trafficking, considered to be fundamental
in synapse maintenance, connectivity and finally in
survival.
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